Latest Conference Articles

Neoadjuvant Zytiga Helps Eliminate Some Patients' Prostate Tumors

Combined neoadjuvant treatment with abiraterone acetate (Zytiga) plus standard hormonal therapy before prostatectomy eradicated or nearly eradicated tumors in 34% of patients with localized high-risk prostate cancer.

Combining Two Targeted Therapies Stalls Disease Progression in Melanoma Patients With BRAF Mutations

A combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib has shown promising activity in patients with advanced melanoma.

Olanzapine Proves Effective in Breakthrough CINV

Olanzapine, an antipsychotic medication that is often used off-label, has proved highly effective in controlling breakthrough chemotherapy-induced nausea and vomiting.

Dr. Gomella on Neoadjuvant Hormonal Therapy Plus Zytiga

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, on Neoadjuvant Hormonal Therapy Combined With Abiraterone Acetate

Dr. Chapman on BRAF/MEK Combination for Melanoma

Dr. Paul Chapman, from Memorial Sloan-Kettering Cancer Center, on Combining BRAF and MEK Inhibitors for Advanced Melanoma

Dr. Markman on PCP Awareness of Long-Term Side Effects

Dr. Maurie Markman, Cancer Treatment Centers of America, on Primary Care Physician Awareness of Long-Term Chemotherapy Side Effects

PCPs Highly Unaware of Long-Term Chemotherapy Side Effects

Many primary care providers and some oncologists are unaware of the long-term effects of four chemotherapy drugs used to treat two of the most common forms of cancer.

Dr. Goy on Crizotinib for Pediatric Patients With ALCL

Dr. Andre Goy, from John Theurer Cancer Center, on Crizotinib for Pediatric Patients With ALCL

Crizotinib Active in ALK-Positive Pediatric Cancers

Targeting the ALK gene with the oral agent crizotinib slowed or eliminated signs of tumor growth in pediatric patients with aggressive forms of neuroblastoma, ALCL, and IMTs.

Dr. Kazmi Discusses Olanzapine for Breakthrough CINV

Dr. Shayma Kazmi, from Cancer Treatment Centers of America, on Olanzapine for Breakthrough Chemotherapy-Induced Nausea and Vomiting

Nurses Discuss the Value of the ONS Annual Congress

Five nurses discuss the value of the Oncology Nursing Society (ONS) Annual Congress, which is the largest meeting held specifically for oncology nurses.

Video Highlights From the 2012 ONS Congress

The Oncology Nursing Society (ONS) 37th Annual Congress video highlights, from OncLive TV.

ONS 37th Annual Congress Slideshow

The Oncology Nursing Society (ONS) 37th Annual Congress Picture Slideshow.

Coverage Recap: ONS 37th Annual Congress

A recap of our coverage from the Oncology Nursing Society 37th Annual Congress, in New Orleans, where thousands of oncology nurses gathered and shared valuable clinical insights.

Mary Gullatte Discusses Nursing Shortages

Mary Gullatte, the president of the Oncology Nursing Society, Discusses Nursing Shortages

Carol Bush on the MCA Telehealth Network

Carol Bush, BS, RN, from the The University of Kansas Cancer Center, on the Midwest Cancer Alliance Telehealth Network

All Patients With Colorectal Cancer Should Be Genetically Screened

Universal tumor testing and a detailed personal and family history assessment are recommended for all patients with newly diagnosed colorectal cancer.

Erin McMenamin on HPV-related Head & Neck Cancer

Erin McMenamin, MSN, from the Hospital of the University of Pennsylvania, on HPV-related Head & Neck Cancer Prognosis

ASCO/ONS Chemotherapy Safety Standards Updated to Include All Delivery Settings

The chemotherapy safety standards developed by ASCO and ONS were recently updated to reflect the fact that chemotherapy is delivered in a variety of settings.

Krista Rubin on Managing Ipilimumab-related Dermatitis

Krista Rubin, MS, RN, FNP-BC, from Massachusetts General Hospital Cancer Center, on Managing Ipilimumab-related Dermatitis.

Identifying Appropriate Patients for HER2-Targeted Therapies

Standards for identifying appropriate populations for treatment with HER2-targeted therapies are evolving.

Michael Eckenfels on Bortezomib Delivery Route Changes

Michael Eckenfels, RN, OCN, from MD Anderson Cancer Center, on Changes to the Bortezomib Delivery Route.

Anna Vioral on Multidisciplinary Chemotherapy Safety Standards

Anna Vioral, RN, OCN, from West Penn Allegheny Health System, on Multidisciplinary Chemotherapy Safety Standards.

Treating Patients Enrolled in Clinical Trials

All oncology nurses-not just nurse researchers-will need to understand the fundamentals of clinical trials as patient access to the studies continues to expand.

Oncology Nurses Can Help Mitigate Treatment-Related Side Effects in Head and Neck Cancers

Treatment of head and neck cancer often leaves patients with aftereffects that are bothersome at the very least and life-altering at their worst.

Anne Katz Discusses Cancer and Sexuality

Anne Katz, from the University of Manitoba, Discusses Cancer and Sexuality

Talking to Prostate Cancer Patients About Sipuleucel-T: Nurses Assure Smooth Sailing During Treatment

Nurses play vital roles in assuring that patients with metastatic castration-resistant prostate cancer (mCRPC) are optimally treated with sipuleucel-T.

Oncology Nurses Need to Enhance Their Genetics and Genomics Competency

A pilot study has demonstrated a lag in the integration of genetics and genomics into nursing practice, which is an increasingly required professional skill for oncology nurses.

Jayshree Shah on the Safety and Efficacy of Nilotinib

Jayshree Shah, from John Theurer Cancer Center, on the Safety and Efficacy of Nilotinib for Patients With CML

Kim Kelly on Clinical Practice Guidelines for Mucositis

Kim Kelly, from John Theurer Cancer Center, on the Updated MASCC/ISOO Clinical Practice Guidelines for Mucositis